The asthma market consists of many well-established therapies, including...
The asthma market consists of many well-established therapies, including inhaled agents (e.g., GlaxoSmithKline’s Advair/Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim...
Market Outlook The asthma market in the EU5 is highly competitive. A large...
Market Outlook The asthma market in the EU5 is highly competitive. A large number of approved agents are available inc......
DRG Epidemiology's coverage of asthma comprises epidemiological estimates...
DRG Epidemiology's coverage of asthma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of asthma for each country as well......
DRG Epidemiology’s coverage of asthma comprises epidemiological estimates of...
DRG Epidemiology’s coverage of asthma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of asthma for each country, as well...
DRG Epidemiology’s coverage of asthma comprises epidemiological estimates of...
DRG Epidemiology’s coverage of asthma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of asthma for each country, as...
DRG Epidemiology’s coverage of asthma comprises epidemiological estimates of...
DRG Epidemiology’s coverage of asthma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of asthma for each country, as...
DRG Epidemiology’s coverage of asthma comprises epidemiological estimates of...
DRG Epidemiology’s coverage of asthma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of asthma for each country, as...
MARKET OUTLOOK Despite the availability of multiple anti-inflammatory agents...
MARKET OUTLOOK Despite the availability of multiple anti-inflammatory agents and bronchodilators, considerable unmet need remains for patients with severe asthma. Typica......
The U.S. asthma market has become increasingly crowded with a large number of...
The U.S. asthma market has become increasingly crowded with a large number of approved therapies. Those include several LABA/...
MARKET OUTLOOK Asthma pharmacotherapy has two main goals: to address...
MARKET OUTLOOK Asthma pharmacotherapy has two main goals: to address underlying airway inflammation and promote bronchodilation. Physicians use two types of therapy to achieve these goal......
Market Outlook The dynamics within the LABA/ICS FDC, LAMA, and biological...
Market Outlook The dynamics within the LABA/ICS FDC, LAMA, and biological drug classes will continue to shape the......
Although several effective anti-inflammatory agents and bronchodilators are...
Although several effective anti-inflammatory agents and bronchodilators are available to control disease in mild-to-moderate asthmatics, great unmet need exists in the treatment of severe disease.......
Abstract: Owing to the large diagnosed prevalent population, relatively high...
Abstract: Owing to the large diagnosed prevalent population, relatively high rates of drug treatment across patients of all disease severities, and high rates of polypharma......
MARKET OUTLOOK Asthma pharmacotherapy has two main goals: to address...
MARKET OUTLOOK Asthma pharmacotherapy has two main goals: to address underlying airways inflammation and promote bronchodilation. Physicians use two types of therapy to achieve these goals:......
Device choice has long been a driver of sales of certain inhaled therapies,...
Device choice has long been a driver of sales of certain inhaled therapies, especially those available in multiple inhalers. With generic LAMA...
Emerging Therapies: Nucala (US) is a three-wave, syndicated, detailed,...
Emerging Therapies: Nucala (US) is a three-wave, syndicated, detailed, expanded analysis that tracks the introduction of Nucala, the first IL-5 inhibitor approved to treat eosinophilic asthma. Th......
Owing to the large diagnosed prevalent population, high rates of drug treatment...
Owing to the large diagnosed prevalent population, high rates of drug treatment across patients of all disease severities, and high rates of polypharmacy—particularly among the moderate/severe popu......
Using national patient-level claims data, this report analyzes physician...
Using national patient-level claims data, this report analyzes physician adherence to the treatment guidelines by exploring the use of key therapies in the newly diagnosed and recently treated pati......
Emerging Therapies: Nucala (US) is a three-wave syndicated detailed expanded...
Emerging Therapies: Nucala (US) is a three-wave syndicated detailed expanded analysis that specifically tracks the introduction of Nucala, the first IL-5 inhibitor approved to treat eosinophilic......
Asthma treatment generally includes rescue therapy to relieve acute...
Asthma treatment generally includes rescue therapy to relieve acute exacerbations and maintenance therapy to prevent future attacks. A wide array of well-established therapies spanning multiple cla......
